37 Results for "

synergy

" in MedChemExpress (MCE) Product Catalog:
Products (37)

37 Results for "synergy" in MCE Product Catalog:

19
19 Publications Verification
Cat. No.: HY-130250
CAS No.: 2387704-62-1
Purity:  99.64%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-136555
CAS No.: 1595278-21-9
Purity:  99.93%
Research Areas:  

Inflammation/Immunology

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12376
CAS No.: 256376-24-6
Purity:  99.60%
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99275
CAS No.: 1262787-83-6
Synonyms: AMG-888; U3-1287

Target:  

EGFR Akt ERK PARP Survivin

Research Areas:  

Cancer

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-139287
CAS No.: 823830-85-9
Purity:  99.69%
Research Areas:  

Cancer

M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162859
CAS No.: 2565637-94-5
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC50 value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .
loading...
    loading...
Cat. No.: HY-138832
CAS No.: 1619923-32-8
Purity:  99.85%
Synonyms: APG-1252-M1
Research Areas:  

Cancer

BM-1244 (APG-1252-M1) is a Bcl-xL/Bcl-2 inhibitor with Kis of 134 nM and 450 nM. BM-1244 has anti-tumor effects by inducing apoptosis and suppressing tumor growth. BM-1244 can induce cytochrome C and Smac release from mitochondria with caspase-3 and PARP cleavage. BM-1244 exhibits synergy with chemotherapy in vivo. BM-1244 can be studied in research for colorectal cancer, acute myeloid leukemia and gastric cancer .
loading...
    loading...
Cat. No.: HY-125390
CAS No.: 226907-52-4
Purity:  99.41%
Synonyms: CL-087
Research Areas:  

Inflammation/Immunology Cancer

SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .
loading...
    loading...
Cat. No.: HY-154949
CAS No.: 326901-92-2
Purity:  99.83%
Target:  

WDR5

Research Areas:  

Cancer

WDR5-IN-6 is a WDR5 inhibitor, targeting to WBM site. WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. WDR5-IN-6 shows high synergy with OICR-9429 (HY-16993), a WDR5 inhibitor targeting to WIN site. WDR5-IN-6 can be used for reasearch in neuroblastoma .
loading...
    loading...
Cat. No.: HY-P99277
CAS No.: 1245634-25-6
Synonyms: Anti-C. difficile Toxin A Recombinant Antibody

Target:  

Inhibitory Antibodies

Research Areas:  

Infection

Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
loading...
    loading...
Cat. No.: HY-P991214
CAS No.: 339986-90-2
Synonyms: EMD 273066; huKS-IL2

Target:  

Interleukin Related

Research Areas:  

Cancer

Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
loading...
    loading...
Cat. No.: HY-162382
CAS No.: 2764833-47-6
Target:  

PI3K Akt mTOR

Research Areas:  

Cancer

KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .
loading...
    loading...
Cat. No.: HY-153384
CAS No.: 1958290-51-1
Purity:  99.39%
Research Areas:  

Cancer

EAPB 02303 is a microtubule-disrupting agent and inhibitor. EAPB 02303 induces mitosis arrest and impairment of spindle assembly. Thus, EAPB 02303 induces apoptosis and exhibits antitumor activity. EAPB 02303 also exhibits a potent synergy with Paclitaxel (HY-B0015) at lower concentrations .
loading...
    loading...
Cat. No.: HY-W099540
CAS No.: 5538-95-4
Target:  

Bacterial

Research Areas:  

Infection

OES2-0017 shows potent synergy with polyamines and growth-inhibitory effects at the low micromolar range. OES2-0017 inhibits spermine/spermidine acetyltransferase (SpeG) (IC50: 34.82 μM ) and other polyamine detoxification enzymes in low concentrations, perturbed the bacterial membrane in higher concentrations .
loading...
    loading...
Cat. No.: HY-13312A
CAS No.: 1008448-19-8
Research Areas:  

Cancer

GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC50 values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research .
loading...
    loading...
Cat. No.: HY-P11059
Synonyms: Reps1 peptide
Target:  

Peptides

Research Areas:  

Cancer

MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines .
loading...
    loading...
Cat. No.: HY-15882
CAS No.: 1200127-66-7
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .
loading...
    loading...
Cat. No.: HY-113526
CAS No.: 100557-04-8
AR-12463 is a derivative of Trapidil (HY-B1016). AR-12463 inhibits the conversion of [14C]acetate to cholesterol. AR-12463 significantly reduces the elevation of total cholesterol in rabbit serum and prevents cholesterol incorporation into tissues. AR-12463 can be used to study atherosclerosis.
loading...
    loading...
Cat. No.: HY-118487A
CAS No.: 940061-39-2
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

OB-24 free base is a compound that potently and selectively inhibits heme oxygenase 1 (HO-1) and has the potential to inhibit advanced prostate cancer. OB-24 significantly reduces protein carbonylation and the formation of reactive oxygen species by selectively inhibiting HO-1 activity in prostate cancer cells. OB-24 significantly inhibited cell proliferation in vitro and inhibited tumor growth and lymph node and lung metastasis in vivo. OB-24 exhibits powerful synergy when used in combination with Taxol .
loading...
    loading...
Cat. No.: HY-123577
CAS No.: 2098621-17-9
Research Areas:  

Cancer

TPC-144 is a LSD1/KDM1A inhibitor. TPC-144 inhibits LSD1, and leads to a decrease in the protein level of DNMT1, causing low methylation of the LINE-1 element. TPC-144 can also produce a synergistic effect with Decitabine (HY-A0004) (a DNMT inhibitor), jointly promoting DNA demethylation and thereby inducing differentiation and apoptosis of leukemia cells. TPC-144 has also demonstrated anti-tumor efficacy in acute myeloid leukemia (AML) models. TPC-144 can be used for the study of AML .
loading...
    loading...